| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
3 |
/ |
2017 |
|
|
|
| |
Data sporządzenia: |
2017-03-03 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
The Update Regarding Distribution and Product Platform Strategy for Epidural Instrument
|
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, "the Company", "the Issuer"_,
today announced it has begun its clinical rollout for the epidural instrument in the
Middle East and North Africa _MENA_ regions, by initiating clinical evaluations at
key hospitals in the United Arab Emirates and in Lebanon. Given the extensive published
clinical data supporting successful epidural catheter placement in patients with complex
comorbidities, clinicians and key opinion leaders in these territories have expressed
further interest in broadening the technique scope into challenging thoracic epidural
procedures, as well as extending its use into pediatric cases.
The Company is also continuing its collaboration with key opinion leaders in Italy
with a focus on expanding its clinical utilization at key hospitals in Rome, Florence,
Naples and Pesaro, which resulted in additional scientific data accepted for presentation
at the upcoming meeting of the European Society for Anesthesiology to be held in Geneva,
Switzerland from June 3-5, 2017. Euroanaesthesia is Europe’s largest annual event
showcasing the latest and the most relevant knowledge with medical experts active
in the fields of anesthesia, perioperative medicine, intensive care, emergency medicine
and pain treatment.
The Issuer had a successful showing at Arab Health 2017, which is the largest gathering
of healthcare and trade professionals in the MENA region and the 2nd largest healthcare
exhibition and congress in the world. Numerous distributors from the MENA and the
Asia/Pacific regions expressed the interest in distribution of its epidural and intra-articular
injection instruments.
The Board of Directors of the Company believes that DPS Dynamic Pressure Sensing Technology™
will continue to lead the way as a superior alternative to the more expensive technologies
such as ultrasound and fluoroscopy that are being used to identify the epidural space.
A recent clinical publication in the Journal Regional Anesthesia and Pain Medicine
independently confirmed the lower failure rates of pressure-based epidural waveform
analysis. CompuFlo™ Epidural Instrument is the first commercial product to come to
market with waveform-generating dynamic pressure sensing capabilities.
The Board of Directors of the Issuer is further encouraged by the interest in the
epidural instruments by medical practitioners in Europe and the MENA regions, including
the use of its instrument for patients with complex co-morbidities, as well as prospects
of intended use into pediatric patients.
|
|
|
RB_ASO: The Update Regarding Distribution and Product Platform Strategy for Epidural Instrument
